CA
VRTX icon

Crewe Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Crewe Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Sell
500
-4
-0.8% -$1.86K 0.02% 201
2025
Q4 		$228K Buy
504
+3
+0.6% +$1.29K 0.02% 196
2025
Q3 		$196K Buy
501
+109
+28% +$45.6K 0.02% 208
2025
Q2 		$175K Sell
392
-7
-2% -$3.23K 0.02% 168
2025
Q1 		$193K Sell
399
-1
-0.3% -$466 0.03% 138
2024
Q4 		$161K Sell
400
-163
-29% -$75.6K 0.02% 162
2024
Q3 		$262K Buy
563
+43
+8% +$20.7K 0.03% 125
2024
Q2 		$244K Buy
520
+3
+0.6% +$1.3K 0.03% 158
2024
Q1 		$216K Buy
+517
New +$219K 0.03% 163
2023
Q3 		– Sell
-552
Closed -$194K – 915
2023
Q2 		$194K Buy
552
+26
+5% +$8.76K 0.03% 139
2023
Q1 		$166K Sell
526
-80
-13% -$24K 0.02% 175
2022
Q4 		$175K Sell
606
-105
-15% -$32K 0.03% 167
2022
Q3 		$206K Buy
711
+37
+5% +$10.6K 0.04% 142
2022
Q2 		$190K Buy
674
+209
+45% +$55.9K 0.04% 138
2022
Q1 		$121K Buy
465
+320
+221% +$75.9K 0.02% 159
2021
Q4 		$32K Buy
+145
New +$28.2K 0.01% 224
2020
Q4 		– Sell
-30
Closed -$8K – 646
2020
Q3 		$8K Buy
+30
New +$8.28K ﹤0.01% 285

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Crewe Advisors's VRTX Position: Q1 2026 in Review

Crewe Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 0.79% in Q1 2026, selling an estimated $1.86K and leaving 500 shares worth $223K. The position accounts for 0.02% of the portfolio, ranked #201.

Crewe Advisors first reported a position in VRTX in Q3 2020 and has held it in 17 quarters since. The position peaked at $262K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Crewe Advisors held 500 shares of Vertex Pharmaceuticals worth $223K as of Q1 2026.
  • Crewe Advisors sold 4 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.86K.
  • Vertex Pharmaceuticals made up 0.02% of Crewe Advisors's portfolio in Q1 2026, its #201 holding.
  • Crewe Advisors first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 17 quarters since.
  • Crewe Advisors's Vertex Pharmaceuticals position peaked at $262K in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.